Filing Flows › Orchestra BioMed Holdings (OBIO) › R&D spending
Orchestra BioMed Holdings (OBIO) R&D spending by quarter
Orchestra BioMed Holdings' R&D spending was $16.6M in Q2 2026 (second quarter 2026), +5% from Q1 2026. Over the last 7 quarters it ranged from $11.0M (Q4 2024) to $16.8M (Q4 2025).
| Quarter | R&D spending | Q/Q | Y/Y |
|---|---|---|---|
| Q2 2026 | $16.6M | +5% | +20% |
| Q1 2026 | $15.8M | -6% | +17% |
| Q4 2025 | $16.8M | +20% | +53% |
| Q3 2025 | $14.0M | +1% | — |
| Q2 2025 | $13.9M | +3% | — |
| Q1 2025 | $13.5M | +23% | — |
| Q4 2024 | $11.0M | — | — |
Q2 2026 at a glance
Orchestra BioMed Holdings, Q2 2026: revenue $88K (-90% year over year), net loss $23.8M, operating cash flow −$19.3M. The chart follows the revenue to costs, profit and cash.
Questions
What is Orchestra BioMed Holdings' R&D spending?
Orchestra BioMed Holdings' R&D spending was $16.6M in Q2 2026 (second quarter 2026), +5% from Q1 2026.
How has Orchestra BioMed Holdings' R&D spending changed?
Over the last 7 quarters it ranged from $11.0M (Q4 2024) to $16.8M (Q4 2025).
Q2 2026 results → · How Orchestra BioMed Holdings makes money →